Literature DB >> 18990750

Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk.

Michelle Cotterchio1, Beatrice A Boucher, Michael Manno, Steven Gallinger, Allan B Okey, Patricia A Harper.   

Abstract

Colorectal cancer literature regarding the interaction between polymorphisms in carcinogen-metabolizing enzymes and red meat intake/doneness is inconsistent. A case-control study was conducted to evaluate the interaction between red meat consumption, doneness, and polymorphisms in carcinogen-metabolizing enzymes. Colorectal cancer cases diagnosed 1997 to 2000, ages 20 to 74 years, were identified through the population-based Ontario Cancer Registry and recruited by the Ontario Family Colorectal Cancer Registry. Controls were sex-matched and age group-matched random sample of Ontario population. Epidemiologic and food questionnaires were completed by 1,095 cases and 1,890 controls; blood was provided by 842 and 1,251, respectively. Multivariate logistic regression was used to obtain adjusted odds ratio (OR) estimates. Increased red meat intake was associated with increased colorectal cancer risk [OR (> 5 versus < or = 2 servings/wk), 1.67 (1.36-2.05)]. Colorectal cancer risk also increased significantly with well-done meat intake [OR (> 2 servings/wk well-done versus < or = 2 servings/wk rare-regular), 1.57 (1.27-1.93)]. We evaluated interactions between genetic variants in 15 enzymes involved in the metabolism of carcinogens in overcooked meat (cytochrome P450, glutathione S-transferase, UDP-glucuronosyltransferases, SULT, NAT, mEH, and AHR). CYP2C9 and NAT2 variants were associated with colorectal cancer risk. Red meat intake was associated with increased colorectal cancer risk regardless of genotypes; however, CYP1B1 combined variant and SULT1A1-638G>A variant significantly modified the association between red meat doneness intake and colorectal cancer risk. In conclusion, well-done red meat intake was associated with an increased risk of colorectal cancer regardless of carcinogen-metabolizing genotype, although our data suggest that persons with CYP1B1 and SULT1A1 variants had the highest colorectal cancer risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990750      PMCID: PMC2751598          DOI: 10.1158/1055-9965.EPI-08-0341

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  62 in total

1.  Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma.

Authors:  E Fritsche; T Brüning; C Jonkmanns; Y Ko; H M Bolt; J Abel
Journal:  Pharmacogenetics       Date:  1999-06

Review 2.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

3.  Simulation study of confounder-selection strategies.

Authors:  G Maldonado; S Greenland
Journal:  Am J Epidemiol       Date:  1993-12-01       Impact factor: 4.897

Review 4.  Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins.

Authors:  F J Gonzalez; H V Gelboin
Journal:  Drug Metab Rev       Date:  1994       Impact factor: 4.518

5.  Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis.

Authors:  M P de Leon; M Pedroni; P Benatti; A Percesepe; C Di Gregorio; M Foroni; G Rossi; M Genuardi; G Neri; F Leonardi; A Viel; E Capozzi; M Boiocchi; L Roncucci
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

6.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants.

Authors:  T Shimada; J Watanabe; K Kawajiri; T R Sutter; F P Guengerich; E M Gillam; K Inoue
Journal:  Carcinogenesis       Date:  1999-08       Impact factor: 4.944

Review 7.  Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.

Authors:  D W Nebert; M Ingelman-Sundberg; A K Daly
Journal:  Drug Metab Rev       Date:  1999-05       Impact factor: 4.518

8.  Familial aggregation of colorectal cancer in the general population.

Authors:  B Carstensen; H Soll-Johanning; E Villadsen; J O Søndergaard; E Lynge
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

9.  Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes.

Authors:  G J Hammons; D Milton; K Stepps; F P Guengerich; R H Tukey; F F Kadlubar
Journal:  Carcinogenesis       Date:  1997-04       Impact factor: 4.944

Review 10.  Drug-mediated inactivation of cytochrome P450.

Authors:  M Murray
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-07       Impact factor: 2.557

View more
  55 in total

1.  Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma.

Authors:  Leah M Ferrucci; Amanda J Cross; Marc J Gunter; Jiyoung Ahn; Susan T Mayne; Xiaomei Ma; Stephen J Chanock; Meredith Yeager; Barry I Graubard; Sonja I Berndt; Wen-Yi Huang; Richard B Hayes; Rashmi Sinha
Journal:  World Rev Nutr Diet       Date:  2010-04-30       Impact factor: 0.575

2.  CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis.

Authors:  Guo-Wu Zhou; Jia Hu; Qiang Li
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

3.  A high frequency missense SULT1B1 allelic variant (L145V) selectively expressed in African descendants exhibits altered kinetic properties.

Authors:  Zachary E Tibbs; Amber L Guidry; Josie L Falany; Susan A Kadlubar; Charles N Falany
Journal:  Xenobiotica       Date:  2017-02-05       Impact factor: 1.908

4.  Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans.

Authors:  Michael A Malfatti; Edward A Kuhn; Kenneth W Turteltaub; Selwyn M Vickers; Eric H Jensen; Lori Strayer; Kristin E Anderson
Journal:  Chem Res Toxicol       Date:  2016-03-08       Impact factor: 3.739

5.  Xenobiotic metabolizing genes, meat-related exposures, and risk of advanced colorectal adenoma.

Authors:  Lea M Ferrucci; Amanda J Cross; Marc J Gunter; Jiyoung Ahn; Susan T Mayne; Xiaomei Ma; Stephen J Chanock; Meredith Yeager; Barry I Graubard; Sonja I Berndt; Wen-Yi Huang; Richard B Hayes; Rashmi Sinha
Journal:  J Nutrigenet Nutrigenomics       Date:  2011-04-06

6.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

Review 7.  Sulfotransferase genetic variation: from cancer risk to treatment response.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Drug Metab Rev       Date:  2013-09-06       Impact factor: 4.518

8.  Pharmacogenetics of SULT1A1.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

Review 9.  Genetic unraveling of colorectal cancer.

Authors:  Sabha Rasool; Vamiq Rasool; Tahira Naqvi; Bashir A Ganai; Bhahwal Ali Shah
Journal:  Tumour Biol       Date:  2014-02-27

10.  Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

Authors:  Vibeke Andersen; Mette Ostergaard; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2009-11-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.